Immune-related corneal ulcer caused by camrelizumab
10.3760/cma.j.cn114015-20241216-00205
- VernacularTitle:卡瑞利珠单抗致免疫相关角膜溃疡
- Author:
Yan ZHENG
1
;
Yufeng CHEN
1
;
Xiaomin CHEN
1
;
Min KE
1
Author Information
1. 武汉大学中南医院眼科，武汉 430071
- Publication Type:Journal Article
- Keywords:
Corneal ulcer;
Immune checkpoint inhibitor;
Camrelizumab;
Adenocarcinoma of lung;
Immune-related adverse events
- From:
Adverse Drug Reactions Journal
2025;27(10):632-634
- CountryChina
- Language:Chinese
-
Abstract:
A 57-year-old male patient with lung adenocarcinoma accompanied by brain metastasis received radiotherapy and chemotherapy with poor efficacy. Subsequently, he was given camrelizumab at a dose of 200 mg intravenously once every 21 days, combined with intermittent chemotherapy or targeted drug therapy. After 22 months, the patient developed right eye pain with visual loss. Slit lamp examination showed a transverse oval shallow ulcer with clear boundary, clean surface and a maximum diameter of about 6 mm in the center of the cornea of the right eye, with positive fluorescein staining. Immune-related corneal ulcers due to camrelizumab were considered. Camrelizumab was discontinued, and the patients′ ocular symptoms were gradually improved after systemic and local glucocorticoid and corneal repair drugs were given. Seven months later, due to the patient did not follow the doctor′s advice to replace eye drops, overuse of glucocorticoid occurred, resulting in perforation of the original ulcer. The glucocorticoid-containing eye drops was discontinued, the patient underwent amniotic membrane grafting combined with amniotic membrane patching on the right eye, and the patient's condition was improved.
